Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMRT plus nab-paclitaxel and platinum for postoperative recurrent cervical cancer (Phase II)
ChiCTR2000038427Phase 2Recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Sep 2020
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nab-paclitaxel, cisplatin and carboplatin in cervical cancer (mCC), sponsored by Fudan University Shanghai Cancer Center. Primary endpoint: 3-year overall survival. Started Sep 2020; status: recruiting.
02
Drugs
nab-paclitaxelcisplatincarboplatin
03
Conditions
cervical cancer (mCC)
Beyond the preview
Go deeper on ChiCTR2000038427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000038427.